Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injection site pain comparison of two semaglutide formulations
2019-003654-83Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of semaglutide (2 arms), sponsored by Novo Nordisk. Primary endpoint: Intensity of injection site pain. Started Oct 2019; status: completed.
02
Drugs
Beyond the preview
Go deeper on 2019-003654-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003654-83.